Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28205022 | 0.98 | MAPT (0.58) | MAPTKDM4ENPC1POLBRAB9A | |
| SCHEMBL12998745 | 0.83 | TDP1 (0.69) | MAPTKDM4ENPC1POLBRAB9A | |
| Hydrochloric Acid SCHEMBL17362383 | 0.82 | TDP1 (0.67) | MAPTKDM4ENPC1POLBRAB9A | |
| SCHEMBL9472568 | 0.80 | MAPT (0.65) | MAPTKDM4ENPC1POLBRAB9A | |
| SCHEMBL6754521 | 0.80 | KDM4E (0.59) | MAPTKDM4ENPC1POLBRAB9A | |
| SCHEMBL15154757 | 0.78 | NPC1 (0.58) | MAPTKDM4ENPC1POLBRAB9A | |
| SCHEMBL16632333 | 0.78 | ACLY (0.54) | KDM4ETDP1AKR1C3AKR1C2GRIK1 | |
| SCHEMBL17627435 | 0.78 | GRIK1 (0.58) | KDM4ERAB9AGRIK1ALDH1A1 | |
| SCHEMBL15545327 | 0.78 | PTPRC (0.50) | MAPTKDM4ENPC1POLBRAB9A | |
| SCHEMBL17627412 | 0.78 | KEAP1 (0.53) | MAPTKDM4ENPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | MAPT 4413/4885KDM4E 1934/4885NPC1 83/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | MAPT 4286/4885KDM4E 4472/4885NPC1 1821/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | MAPT 3090/4885KDM4E 3541/4885NPC1 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.